Raymond James Financial Services Advisors
VTGN icon

Raymond James Financial Services Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-358
Closed -$13K – 3435
2022
Q1 		$13K Buy
+358
New +$15.6K ﹤0.01% 3282

Other funds holding VTGN

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial Services Advisors's VTGN Position: Q2 2022 in Review

Raymond James Financial Services Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2022, closing a stake of 358 shares — an estimated $13K sold.

Raymond James Financial Services Advisors first reported a position in VTGN in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 112 funds tracked by Wall St. Rank hold VTGN as of Q2 2022.

  • Raymond James Financial Services Advisors reported no remaining VistaGen Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 358 VistaGen Therapeutics shares in Q2 2022, an estimated $13K.
  • Raymond James Financial Services Advisors first reported a position in VistaGen Therapeutics in Q1 2022 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's VistaGen Therapeutics position peaked at $13K in Q1 2022.
  • 112 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.